Waldenstrom's Macroglobulinemia Clinical Trials (April 2026): 32 Recruiting Interventional Studies

Last updated: April 19, 2026

Current Clinical Trial Landscape

About Waldenstrom's macroglobulinemia (WM):

WM is a rare B-cell lymphoma characterized by IgM-producing lymphoplasmacytic cells in the bone marrow. Most patients have MYD88 L265P mutation (~95%). Treatment is typically deferred until symptomatic.

Active research areas in 2026:

BTK inhibitors (14 trials): ibrutinib, zanubrutinib, next-gen agents
Rituximab combinations (7 trials)
BCL2 inhibitors (venetoclax)
CAR-T and bispecific antibodies

Standard of care: Watch & wait until symptomatic. First-line: BTK inhibitors (zanubrutinib, ibrutinib) or rituximab-based regimens (BR, R-CHOP). BTK inhibitors preferred for MYD88-mutated patients.

Recruiting Trials by Treatment Setting

First-Line (Treatment-Naive)

For patients requiring first treatment:

NCT03697356 - R-VRD (rituximab, bortezomib, lenalidomide, dex) followed by lenalidomide maintenance

Relapsed/Refractory

After progression on prior therapy:

NCT04830137 - NX-2127 (BTK degrader) for relapsed B-cell malignancies
NCT06340737 - CD22 CAR-T for recurrent/refractory disease
NCT05294731 - BGB-16673 (Bruton tyrosine kinase degrader)
NCT07464210 - Nemtabrutinib + bortezomib + rituximab for WM (Phase 2)

Trials by Treatment Approach

BTK Inhibitors (14 trials)

BTK inhibitors are highly effective in WM, especially with MYD88 mutation. Next-generation agents and BTK degraders are being tested. View all →

Rituximab Combinations (7 trials)

Anti-CD20 antibody combinations remain important, especially for patients who cannot tolerate BTK inhibitors. View all →

BCL2 Inhibitors

Venetoclax shows activity in WM and is being studied in combinations.

CAR-T and Cellular Therapy

Emerging approaches for heavily pretreated patients.

NCT06340737 - CD22 CAR-T cells

Frequently Asked Questions

How do I find Waldenstrom's macroglobulinemia clinical trials?

Paste your medical summary into ClinTrialFinder to get AI-matched WM trials in minutes. The tool considers your MYD88 mutation status, CXCR4 status, and prior treatments including BTK inhibitor history.

What Waldenstrom's macroglobulinemia trials are currently recruiting?

There are 32 recruiting interventional trials for Waldenstrom's macroglobulinemia including next-generation BTK inhibitors, CAR-T cell therapy, bispecific antibodies, and novel targeted agents.

Find WM Trials Matched to Your Situation

Use ClinTrialFinder's AI-powered matching to find trials based on your specific condition and treatment history.

Find Matching Trials